{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Finite Therapy of Chronic Hepatitis B infection: Cons
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Description
Method of Participation in the Learning Process/Evaluation Method Successful completion of this activity includes reading the entire article and successfully completing the post-quiz and an evaluation form. Getting the Most out of the Activity As you prepare to participate in this activity, please reflect on your practice and your patients and identify clinical challenges you hope to have addressed. While participating in the training, identify ways you can use newly acquired knowledge, strategies, and skills to enhance patient outcomes and your own professional development.Learning Objectives
After completing this continuing education activity you will be able to:
- Identify clinical situations in which there is universal agreement to discontinue HBV.
- Use demographic, biochemical and serologic parameters to identify patients who will benefit most and least from finite therapy for CHB.
- Discuss knowledge gaps that contribute to uncertainty around patient selection and long-term monitoring for adopting finite therapy in chronic hepatitis B infection.
- Explain considerations regarding finite therapy for chronic hepatitis B infection, including (Cost, Adherence, Safety/Adverse effects, Patient preference, Risk of relapse, and Long-term outcomes).
Disclosures
Yao-Chun Hsu advises, is on the speakers' bureau for, and received grants from Gilead. He advises Sysmex. He is on the speakers' bureau for AbbVie, Bristol-Myers Squibb, Merck Sharp and Dohme, and Novartis. The faculty, planners, and staff have no relevant financial relationships with any ineligible organizations regarding this educational activity.
Lippincott CME Institute has identified and mitigated all relevant financial relationships regarding this educational activity.
Price:
$30.00
Credits:
- ACCME 1.0 CME
Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.Lippincott Continuing Medical Education Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Professions:
Physician
Test Code: CLD0424E
Published: April 2024
Expires: 3/31/2026
Sources:
Clinical Liver Disease
Required Passing Score: 4/5 (80%)
Categories:
Hepatology
Specialties:
Hepatology
Topics:
Chronic Hepatitis B Infection